23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results
26 mai 2022 16h05 HE
|
23andMe Holding Co.
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services...
23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results
12 mai 2022 16h10 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
15 mars 2022 06h45 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access,...
23andMe to Present at Cowen 42nd Annual Health Care Conference
25 févr. 2022 08h30 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand,...
23andMe to Present at Citi’s 2022 Virtual Healthcare Conference
17 févr. 2022 09h00 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand,...
23andMe Reports FY2022 Third Quarter Financial Results
10 févr. 2022 16h04 HE
|
23andMe Holding Co.
Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of...
23andMe to Report FY2022 Third Quarter Financial Results
27 janv. 2022 16h05 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial...
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program
18 janv. 2022 06h55 HE
|
23andMe Holding Co.
GSK extends exclusive target discovery period of collaboration for a fifth year to discover and validate novel drug targets using 23andMe’s proprietary genetic and health survey database 23andMe...
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
10 janv. 2022 08h00 HE
|
23andMe Holding Co.
SUNNYVALE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today received FDA clearance for a genetic health...
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
06 janv. 2022 09h00 HE
|
23andMe Holding Co.
23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey...